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Abstract In this study, we investigate the underlying
mechanisms of antibody-mediated inflammation in the brain.
We show that immune complexes formed in the brain
parenchyma generate a robust and long-lasting inflammatory
response, characterized by increased expression of the
microglia markers CD11b, CD68 and FcRII/III, but no neu-
trophil recruitment. In addition to these histological changes,
we observed transient behavioural changes that coincided
with the inflammatory response in the brain. The inflamma-
tory and behavioural changes were absent in Fc-gamma chain
(Fcc)-deficient mice, while C1q-deficient mice were not dif-
ferent from wild-type mice. We conclude that, in the presence
of antigen, antibodies can lead to a local immune complex-
mediated inflammatory reaction in the brain parenchyma and
indirectly induce neuronal tissue damage through recruitment
and activation of microglia via Fcc receptors. These obser-
vations may have important implications for the development
of therapeutic antibodies directed against neuronal antigens
used for therapeutic intervention in neurological diseases.
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Introduction
An inevitable consequence of an ageing population is an
increased incidence of neurodegeneratative diseases, such as
Alzheimer’s disease, Parkinson’s disease and age-related
macular degeneration. Recent experimental and clinical
studies have provided evidence for both innate and adaptive
immune activation in the pathogenesis of these debilitating
disorders. For example, microglia activation is typically
associated with any neuropathology and there is increasing
evidence that (auto)-antibodies against brain-reactive anti-
gens are associated with clinical symptoms [11, 28]. Genome
wide association studies (GWAS) in AD [21] and AMD [35]
provide further evidence for the involvement of the immune
system in disease pathogenesis. The young and healthy CNS
is an immune privileged site where immune surveillance and
inflammation is tightly regulated [4, 15]. The presence of an
intact blood–brain barrier (BBB) combined with the unique
microenvironment of the brain, ensures that the reactions to
an inflammatory challenge, such as endotoxin (LPS) or
cytokines, are attenuated [30]. We and others have shown
that the healthy CNS parenchyma is able to modify leucocyte
responses to acute injury [2, 3], but it is less clear if, and how,
the brain controls antibody-mediated responses, and whether
these responses are altered under neuroinflammatory con-
ditions or age-related pathology. Antibodies may mediate
tissue damage when they form immune complexes and
recruit cytotoxic effector cells, such as macrophages via their
Fcc receptors (FccRs) or by activating complement [34]. The
interaction with FccRs stimulates cell signalling in the
effector cell that ultimately results in phagocytosis and/or
release of inflammatory or cytotoxic mediators. These
responses are well described in peripheral tissues, using the
(reversed) Arthus reaction, a well accepted experimental
model of antibody-mediated inflammation [10]. In the
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presence of an intact BBB, IgG is only present in the healthy
brain at very low levels relative to plasma levels [32] and the
effector cells, such as microglia and perivascular macro-
phages, express detectable but low levels of FccRs [31].
However, expression of FccRs is enhanced on microglia
following treatment with IFN-c, TNF-a and LPS in vitro
[26], after intracerebral injection of LPS [17] and, as we have
recently shown, during experimental chronic neurodegen-
eration [27]. Despite these observations we have limited
knowledge of the consequences of immune complex for-
mation in the CNS, the associated inflammatory response
and the function of the different FccRs in the CNS. The
growing incidence of neurodegenerative conditions in the
human population, and the interest in the use of antibody-
based immunotherapy to treat these diseases, highlights the
need to understand the possible consequences of antibody-
mediated inflammation in the CNS parenchyma.
Davidoff et al. [12] were the first to describe antibody-
mediated inflammation in the brain and showed that the
Arthus reaction in the rabbit brain resembled that seen in
the skin and other peripheral tissues. However, it is likely
that the relatively crude techniques used in this study
significantly disturbed the unique vasculature and micro-
environment of the brain making it difficult to interpret the
results. More recently, Lister and Hickey [25] reported that
immune complexes can be formed in the microvasculature
of the brain, resulting in complement activation, increased
microvascular permeability and leucocyte adhesion. How-
ever, this study was restricted to the role of immune
complexes in the meningeal compartment and not in the
brain parenchyma.
The aim of the current study was to investigate the acute
and long-term consequences of immune complex forma-
tion in the brain parenchyma, using a model antigen widely
used in the study of peripheral antibody-mediated respon-
ses. We show that immune complex formation in the brain
parenchyma results in neuroinflammatory and behavioural
changes that depend on FccR interactions. Apart from
further understanding of antibody-mediated responses in
the brain in general, our study provides insight into the
complications reported following anti-Ab immunization,
such as micro-haemorrhages and increased cerebral amy-
loid angiopathy (CAA) [6, 46, 47].
Materials and methods
Mice
BALB/c mice were obtained from Charles River (Margate,
UK) and bred and maintained in local facilities. Fcc chain
deficient (Fcc-/-) originally described by Takai et al. [42]
were obtained from The Jackson Laboratory and back
crossed onto a BALB/c background. C1q-deficient (C1q-/-
mice were obtained from Dr Aras Kadioglu (Leicester, UK)
with permission from Professor Marina Botto (London, UK)
[7]. Animal experiments were carried out with approval
from the local Committee for Ethics at the University of
Southampton and were performed under a Home Office
license.
Immunization
8 week old BALB/c mice were immunized against oval-
bumin (OVA) by intraperitoneal injection of 50 lg OVA
(Sigma) in the presence of Alum (1:1 ratio, Alum imject,
Pierce). Mice were boosted three times (2, 4 and 6 weeks)
by intraperitoneal injection of 100 lg OVA in saline. Three
days after the last OVA injection, OVA was microinjected
into the striatum.
Immune complex formation
Immune complex-mediated inflammation was initiated by
a cerebral injection of OVA in OVA-immunized or non-
immunized control animals. Mice were anaesthetized by
intraperitoneal injection of 0.1 ml/5 g body weight Avertin
(2,2,2 tribromoethanol in tertiary amyl alcohol) and placed
in a stereotaxic frame (Kopf Instruments, Tujunga, CA,
USA). OVA (10 lg in 1 ll) was injected into the striatum
(bregma ?1 mm anterior, lateral ?1.5 mm, 2.5 mm deep)
by a minimally invasive technique using a fine glass
micropipette with a diameter of \50 lm (Sigma). Tissue
was collected after 24 h, 3 days, 7 days, 14 days and
28 days. These time points were chosen based on the
kinetics of immune complex-mediated inflammation in
peripheral organs [40] or microglial activation in the brain
parenchyma following LPS challenge [17]. Under terminal
anaesthesia, blood samples were collected by cardiac
puncture, and after transcardial perfusion using heparinized
saline, brains and spleen were removed and snap frozen in
OCT embedding medium. For immunohistological exam-
ination and quantification studies, brains were sectioned in
a coronal plane on a cryostat (Leica 17–20).
Immunocytochemistry
Serial sections of brain, 10 lm thick, were air-dried and
fixed in cold ethanol for 10 min at 4 C, and stained for the
presence of immune complexes. Rabbit anti-OVA (Sigma,
UK) was used to detect the antigen OVA and complement
activation was identified using antibodies against C3 (FITC
conjugated rabbit anti-C3, Cappel). Mouse IgG was
identified using FITC labelled F(ab0)2 fragments of goat
anti-mouse IgG (Sigma, UK). Phenotypic changes in mac-
rophages were assessed using rat anti-mouse F4/80 (serotec),
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CD11b (5C6, Serotec), CD68 (FA11, Serotec), MHC class
II (Bioscience) and CD16/CD32 (FCR4G8, FcRII/III, Se-
rotec). The presence of neutrophils was assessed with
MBS-1, an in-house produced polyclonal antibody, gen-
erated as described elsewhere [43]. The presence of
platelets was assessed with a rat anti-mouse gpII1/IIIb mAb
(CD41, Serotec) and T cells using rat anti-mouse CD3
(KT3, Serotec). Biotinylated secondary antibodies and
HRP-conjugated streptavidin were from Vector (UK) and
the chromogen substrate DAB from Sigma (UK). Alexa
Fluor 488 or Alexa Fluor 546 conjugated secondary anti-
bodies were obtained from Invitrogen (Molecular Probes,
Oregon, USA). Mounted sections were cover-slipped using
Vectashield (Hard set, with DAPI, Vector, UK). The
intensity of the macrophage markers CD11b, F4/80 and
MHC class II was quantified using the Leica analysis
software on a Leica microscope. The expression level of
macrophage markers was quantified by taking four images
at 109 magnification per injected hemisphere (field). The
total number of pixels of DAB positive staining per field
was recorded. Data was analysed by One-way ANOVA
followed by Dunnett’s post hoc test. p \ 0.05 was con-
sidered significantly different.
OVA antibody ELISA
Sera from OVA-immunized mice was serially diluted onto
OVA coated plates (10 lg/ml in PBS; maxiSorb, Nunc)
followed by incubation with biotinylated horse-anti-mouse
IgG (Vector, UK) for determination of total OVA-specific
IgG levels. Subclasses were determined by IgG1- and
IgG2a-specific antibodies (Serotec, UK). Binding of OVA-
specific antibodies was detected by poly-streptavidin
(Sanquin, The Netherlands) and visualized using TMB/
H202 substrate (R&D systems, UK).
Assessment of behaviour
Circling behaviour was carried out in an opaque cylindrical
bowl of 10 cm circumference, with a clearly labelled mid-
point that was used as a reference as to how many times the
mouse crosses the line and in which direction. Left and right
turns were counted when the tip of the nose crossed this ref-
erence line, over a 1-min period. The left and right turning
behaviour was measured at day -1 for baseline measurements
and at day 1, 3, 7 and 14 after intracerebral OVA injection.
Statistical analysis
Quantification of immune activation markers and behav-
ioural data was analysed by one-way analysis of variance
(ANOVA) followed, if significant, by Dunnett’s post-test
versus controls using Graphpad Prism software. Values
were expressed as mean ± SEM. A p value \0.05 was
considered to indicate statistical significant difference and
n refers to number of animals per group.
Results
Immune complexes in the brain parenchyma
Mice were sensitized to ovalbumin (OVA) followed by
stereotaxic microinjection of OVA into the striatum to induce
immune complex deposition in the brain parenchyma.
Non-immunized mice received a similar intracerebral
injection of OVA in the striatum and were used as con-
trols. All immunized mice showed high levels of
circulating OVA-specific antibodies, with IC50 values of
[1:1,000,000 in our binding assay to OVA coated plates.
Sera from non-immunized mice were negative (Fig. 1i). In
OVA-sensitized mice, intracerebral injection of OVA
resulted in the accumulation of OVA and IgG in the brain;
the effect was restricted to the injected hemisphere of the
brain although spread over the dorsal half (Fig. 1a, b). At
24 h after intracerebral injection of OVA, immunized mice
showed accumulation of OVA (Fig. 1e) and IgG (Fig. 1f).
Non-immunized mice that received a similar challenge
with OVA did not show accumulation of these proteins
(Fig. 1c–d, g–h). These results suggest that OVA-immu-
nized mice have increased retention of antigen following
intrastriatal challenge. To further investigate and charac-
terize the immune complexes we analysed tissue sections
for co-localization of OVA and IgG and complement
component C3 by double immuno-fluorescent staining
(Fig. 2). At 24 h after injection of OVA, we observed
increased IgG immunoreactivity in the lumen of blood
vessels and found IgG co-localized with C3 (Fig. 2b) and
OVA (Fig. 2e) in the parenchyma. At 7 days after OVA
injection, deposits of C3 and OVA immunoreactivity were
still present in the brain of immunized mice, co-localizing
with IgG around blood vessels (Fig. 2c, f). Immune com-
plexes, as revealed by the co-localization of IgG with C3
and OVA, were observed not only close to the injection
site, but also in association with blood vessels in the cortex,
the leptomeninges and corpus callosum (data not shown).
Non-immunized control mice did not show evidence of
IgG or C3 co-localized with OVA in the brain (Fig. 2a, d).
Together, these data suggest that immune complexes form
in the parenchyma following intracerebral injection of
OVA into sensitized mice, resulting in an accumulation of
IgG and co-localization with C3 and OVA.
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Macrophage/microglial activation
The presence of OVA at the abluminal site of blood vessels
suggests possible phagocytosis of the immune complexes by
perivascular macrophages. Therefore, we next investigated
whether macrophage and microglia activation could be
observed in response to immune complexes. The myeloid
markers CD11b and F4/80 are weakly expressed on
microglia in the parenchyma of non-immunized mice and
MHCII is undetectable. Immune complex formation in the
brain was associated with increased expression of the
CD11b, MHCII and F4/80. At 24 h after intracerebral
injection of OVA, minor changes in expression were
observed, but at 3 and 7 days after intracerebral challenge
with OVA in immunized mice, perivascular macrophages
and microglia changed morphology and phenotype, and
showed markedly increased expression of CD11b, MHCII
and F4/80 (Fig. 3). Quantification revealed that the increase
in CD11b (F(5,18) = 19.92, p \ 0.0001) and MHC class II
(F(5,18) = 7.638, p = 0.0005) was significantly different
from non-immunized mice that received a similar intrace-
rebral injection of OVA (Fig. 3). We found that immune
complex formation also induced increased expression of
FccII/III receptor (FccR), which was already observed at
24 h after OVA injection. This increase in expression was
first detectable on perivascular cells, followed by a clear
expression on parenchymal cells, including microglia, at
later time points (Fig. 3). At 7 days after OVA injection, a
large number of macrophages and microglia showed
increased expression of FccRII/III, while non-immunized
control mice showed minimal expression of FccRs. These
data suggest that immune complex formation induces
microglia activation, possibly initiated by activation and
increased expression of FccRs on perivascular macrophages.
Neuroinflammation in the absence of neutrophils
To investigate if immune complexes in the brain induce
leucocyte recruitment similar to that seen in peripheral tis-
sues, we evaluated brain tissue for the presence of platelets
and neutrophils at various time points after intracerebral
injection of OVA. Immunocytochemical analysis revealed
increased CD41 expression in OVA-immunized mice
(Fig. 4), indicating the presence of platelets. Platelets were
present mainly in and around blood vessels in the injected
hemisphere from 24 h, persisting up to 7 days following
OVA challenge (Fig. 4a–c). Minimal CD41 immunoreac-
tivity was observed in non-immunized control mice
(Fig. 4d–f). In contrast, neutrophils could not be detected in
the brain perivascular space or parenchyma of either
immunized or non-immunized mice (Fig. 4g–l). Injection of
OVA into the skin of an OVA-immunized mouse confirmed
recruitment of neutrophils at a peripheral site following
immune complex formation (Fig. 4m, n).
Fig. 1 Accumulation of OVA and IgG following intracerebral
injection of OVA. OVA-immunized mice (a, b, e, f) or non-
immunized mice (c, d, g, h) received a unilateral injection of OVA
into the striatum and were assessed for the presence of OVA and IgG
24 h later. Immunocytochemical analysis of OVA revealed accumu-
lation of OVA at the injected site of the brains of immunized mice
(a) and not in the injected site of the brain of non-immunized mice
(c). The non-injected hemisphere of the brain of both immunized
(b) and non-immunized mice (d) were negative for OVA immuno-
reactivity. Scale bar 300 lm. A higher magnification shows
accumulation of OVA in association with and around blood vessels
of OVA-immunized mice (e) but not in non-immunized mice (g).
Immunocytochemical staining of IgG showed extravasation from
blood vessels in OVA-immunized mice (f) but not in non-immunized
mice (h). Scale bar 50 lm. Representative data of n = 3 per
treatment group is shown. The experiment was performed twice
independently with comparable results. i Levels of circulating anti-
OVA antibodies (total IgG) were determined by ELISA. Data is
expressed as A450/570 values. Closed symbols and represent OVA-
immunized mice (n = 14) and open symbols represents non-immu-
nized mice (n = 3)
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The long-term consequence of antibody-mediated
neuroinflammation was assessed by staining for CD11b
and CD68 expression at 7, 14 and 28 days after OVA
injections with OVA. Figure 5 shows that expression of
CD11b and CD68 was increased relative to non-immunized
controls at 7 days after intracerebral OVA challenge
(Fig. 5b, f), at 14 days (Fig. 5c, g) and even 28 days after
OVA injection (Fig. 5d, h). Many of these cells had a
rounded appearance indicative of both microglia activation
and possible recruitment of monocytes across the damaged
BBB.
Differential role of complement and Fc receptors
In order to understand the mechanisms underlying OVA–
immune complex-mediated inflammatory changes in the
brain parenchyma, we studied immune complex-mediated
inflammatory responses in the striatum of C1q-/- and Fcc
chain-/- mice. Intracerebral injection of OVA in C1q-/-
mice resulted in an increased expression of CD11b (Fig. 6d),
CD68 (Fig. 6h) and FccR (data not shown), similar to OVA-
immunized wild-type controls (Fig. 6a, e). In contrast, Fcc
chain-/- showed only limited increase in expression of these
macrophage markers (Fig. 6c, g). Comparison of macrophage
activation between non-immunized wild type, OVA-immu-
nized wild type, C1q-/- and Fcc chain-/- mice revealed
significant up-regulation of myeloid markers following OVA
challenge [One-way ANOVA: CD11b (F(3,15) = 19.70,
p \ 0.0001), CD68 (F(3,11) = 46.68, p \ 0.0001) and MHC
class II (F(3,19) = 6.496, p = 0.0044)]. Compared to non-
immunized mice, a Dunnett’s post hoc analysis revealed that
expression of CD11b, MHCII and CD68 was significantly
different in OVA-immunized wild type and C1q-/- mice
only, with no significant difference in OVA-immunized Fcc
chain-/- mice (Fig. 6). The levels of circulating anti-OVA
antibodies were similar in wild-type, C1q-/- and FccR-/-
mice (Fig. 6). These results suggest that FccRs, but not C1q,
play an important role in the inflammatory response following
antibody-mediated inflammation in the brain.
To investigate if T cells are recruited to the brain fol-
lowing antibody-mediated neuroinflammation, we analysed
brain sections for the presence of CD3 positive T cells at
24 h, 7 days and 14 days after intracerebral OVA injection.
Small numbers of CD3? T cells were detected in the
vicinity of blood vessels at both 24 h and 7 days (Fig. 7a,
b). A limited number of CD3? T cells was detected in the
brain parenchyma following immune complex formation
14 days earlier (Fig. 7c) while non-immunized control
mice did not show immunoreactivity for CD3 (Fig. 7d).
Next, we analysed the striatum of OVA-immunized c-/-
mice for the presence of T cells to compare with OVA-
immunized wild-type mice. We found that both strains
Fig. 2 Immune complexes form in the parenchyma and in associa-
tion with the vasculature after intracerebral injection of OVA. Non-
immunized mice or OVA-immunized mice received a unilateral
injection of OVA in the striatum and were assessed for presence of
OVA, IgG and complement C3 at 24 h and 7 days. Data shows IgG in
red co-stained for C3 or OVA in green. At 24 h OVA is present in the
parenchyma and around blood vessels of immunized mice, while at
later time points OVA is largely confined to the vicinity of the
vasculature. Data shown is representative of n = 3 per treatment
group. The experiment was performed twice independently with
comparable results
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showed evidence of CD3? T cells recruitment (Fig. 7e, f),
but very different CD11b immunoreactivity (Fig. 7h, i)
measured 7 days following intracerebral OVA injection.
Behavioural changes
Rotation behaviour was used to investigate the functional
consequences of antibody-mediated inflammation in the
brain parenchyma. Altered rotation behaviour is an indica-
tion of neuronal damage to the striatum, which is elegantly
shown by unilateral injections of the neurotoxin kainic acid
[23]. We measured rotation behaviour over a 1 min period, at
0, 1, 3 or 7 days after intracerebral OVA injections in wild
type and Fcc-/- mice. There was no difference in the
baseline ratio of left/right turns between OVA-immunized
wild-type and OVA-immunized Fcc-/- mice. Intracerebral
OVA injection into the left striatum induced a significant
decrease in the left:right ratio of OVA-immunized WT mice.
A Dunnett’s post hoc test revealed that the alterations were
significantly different from baseline levels when measured
3 days after OVA injection (F(4,31) = 4.165, p = 0.0082,
Fig. 8). Intracerebral OVA injection did not induce changes
in rotation behaviour of OVA-immunized Fcc-/- mice
(F(4,12) = 1.901, p = 0.1751), suggesting an important role
for FccRs in the functional consequences of immune com-
plex formation in the brain (Fig. 8).
Fig. 3 Macrophage and microglia activation in the brain after
intracerebral injection of OVA. OVA-immunized mice or control
non-immunized mice received a unilateral injection of OVA into the
striatum and were assessed for presence of macrophage and microglia
activation. Data shows CD11b, MHCII, F4/80 and FccRII/III
immunoreactivity after 24 h, 3 days or 7 days in OVA-immunized
mice or non-immunized mice. As a positive control for these well-
characterized antibodies spleen tissue from a naı¨ve mouse was used.
The number of DAB-positive pixels (cells and their processes) in
OVA-immunized (black bars) and non-immunized mice (white bars)
was quantified as described in ‘‘Materials and methods’’. Statistical
analysis: One-way ANOVA, Dunnett’s post-test *p \ 0.05. Data
represents the mean of n = 3–5 per treatment and time point. The
experiment was performed twice independently with comparable
results
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Discussion
In this study we have demonstrated that the formation of
immune complexes in the brain parenchyma results in a
localized neuroinflammatory response and associated
behavioural changes. We show that immune complexes
form in association with cerebral blood vessels of OVA-
sensitized mice that have received an intracerebral OVA
challenge. Immune complex formation results in increased
expression of FccRII/III, CD11b, F4/80, CD68 and MHCII
on perivascular macrophages and microglia, observed from
3 days until 4 weeks after antigen challenge. At 24 h we
Fig. 4 Platelet aggregation and neutrophil recruitment in the brain
after intracerebral injection of OVA. OVA-immunized mice or
control mice received a unilateral injection of OVA into the striatum
and were assessed for presence of platelets (CD41) or polymorpho-
nuclear cells (PMN). CD41 (a–f) or PMN (g–l) immunoreactivity is
shown after 1 day, 3 days or 7 days in OVA-immunized mice or non-
immunized mice. As a positive control, OVA was injected in the skin
of an OVA-immunized mouse and assessed for PMN recruitment
(n–m). Representative data of n = 3 per treatment and time point is
shown. The experiment was performed once
Fig. 5 Kinetics of macrophage and microglia activation in the brain
after intracerebral injection of OVA. OVA-immunized mice or non-
immunized mice received a unilateral injection of OVA into the
striatum and brain tissue was assessed for presence of macrophage
activation at day 7, day 14 and day 28. Images in the top panel shows
CD11b immuno-reactivity in control non-immunized mice (a) and
after 7 days (b), 14 days (c) or 28 days (d) in OVA-immunized mice:
CD68 immunoreactivity in the lower panel in control (e) and after
7 days (f), 14 days (g) and 28 days (h) in immunized mice.
Representative data of n = 3 per treatment and time point is shown.
Scale bar 50 lm
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detected platelets adhering to blood vessels, but neutrophils
were not detected at any time point measured. We further
showed that the interaction with FccRs is critical for the
induction of this inflammatory response, since mice lacking
the c-chain did not show the histopathological changes or
altered rotation behaviour, despite similar levels of circu-
lating OVA-specific IgG. Some characteristics of immune
complex-mediated inflammation in the CNS are similar to
those observed in skin or lung inflammation models,
including extravasation of IgG, activation of the comple-
ment cascade and activation of macrophages, but it differs
significantly in the kinetics and cellular components
recruited.
The role of FcR in antibody-mediated
neuroinflammation
The mechanisms of immune complex-mediated inflam-
mation have been extensively studied in peripheral organs,
such as the skin and the lung. It was shown that when
antigen–antibody immune complexes are formed at vas-
cular basement membranes in extracerebral sites, they
Fig. 6 Macrophage and microglia activation in the brain after
intracerebral injection of OVA in wild type, C1q-/- mice and
Fcc-/-. Wild type, C1q-/- mice and Fcc-/- mice on a BALB/c
background were immunized against OVA followed by unilateral
injection of OVA into the striatum. Macrophage and microglia
activation was assessed by immunocytochemistry. Images in the top
panel show CD11b immunoreactivity 3 days after intracerebral
injection of OVA in OVA-immunized wild type (a), non-immunized
wild type (b) or OVA-immunized Fcc-/- (c) and OVA-immunized
C1q-/- (d). Images in the middle panel shows CD68 immunoreac-
tivity 3 days after intracerebral injection of OVA in OVA-immunized
wild type (e), non-immunized wild type (f), OVA-immunized
Fcc-/- (g) and OVA-immunized C1q-/- (h). Scale bar 50 lm.
In the bottom panel the number of DAB-positive pixels/field (cells
and their processes) in the injected hemisphere was quantified as
described in ‘‘Materials and methods’’. Levels of circulating anti-
OVA antibodies (IgG1 and IgG2a) were determined by ELISA. Data
is expressed as A450/570 values. Closed circle and dotted line
represent wild type, closed diamonds represents C1q-/- mice and
closed squares represents Fcc-/- mice. Statistical analysis: One-way
ANOVA, Dunnett’s post-test. Data are expressed as mean of n = 3–6
per group. The experiment was performed once
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trigger inflammation, characterized by oedema, recruitment
of neutrophils, complement activation, and local tissue
damage [10, 41]. It has been suggested that both the
complement system and the activation of Fc receptors
contribute to these inflammatory response [39, 40]. The
effects of immune complex triggered inflammation in the
brain and associated neurobehavioural consequences have
only been sporadically reported in the literature. In 1932,
Davidoff et al. reported that rabbits, sensitized against egg
albumin showed a typical sterile inflammation character-
istic for local anaphylactic symptoms, following
intracerebral challenge with the same antigen. The patho-
logical changes were similar to those described earlier in
the skin [24], including tissue necrosis, oedema, haemor-
rhages and infiltration of leucocytes. The surviving rabbits
developed behavioural changes, including tonic and clonic
muscular contractions and rotating movements. These
observations were the first to describe the devastating
consequences of immune complex formation in the brain,
but due to the relatively crude methodology and many
fatalities, the results should be interpreted with care. Our
study shows that there are important differences between
immune complex-induced inflammation in the brain and
other tissues, but highlight the similar role for FccRs in the
initiation of IgG-mediated inflammation and functional
behavioural changes. Although components of complement
appear less critical our study only used C1q-/- mice, and
to rule out other factors of the complement system further
studies are required. Previous studies using unilateral, in-
trastriatal injections of LPS have shown similar effects on
microglia and circling behaviour [19]. The molecular
mechanisms underlying these changes include increased
expression of MHCII, cytokines and iNOS in the substantia
nigra and striatum, but whether a similar mechanism
explains the behavioural changes in our model remains
undetermined.
Fig. 7 T-cell recruitment after immune complex formation. OVA-
immunized mice received a unilateral injection of OVA into the
striatum and brain tissue was assessed for presence of CD3-positive T
cells at 24 h (a), day 7 (b) and day 14 (c) after OVA injection. Non-
immunized mice were used as control (d, g). OVA-immunized wild
type (e, h) and Fcc-/- (f, i) mice received a unilateral injection of
OVA into the striatum and tissue was analysed for CD3 (d, e, f) or
CD11b (g, h, i) immunoreactivity at 7 days. Representative data of
n = 2–3 per time point are shown. Scale bar 100 lm
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A limited number of studies looked at the mechanism
underlying neuropathology following immune complex
formation, but the role of FccR is largely unknown. Schupf
and William [38] showed that injection of preformed
OVA-anti-OVA immune complexes into the hypothalamus
of rats results in increased food intake. As the effect was
not observed upon injection of immune complexes con-
taining F(ab0)2 fragments, the authors concluded that the
effects observed depend on complement activation. How-
ever, as F(ab0)2 fragments lack Fc, interaction with FccRs,
cannot be excluded. A more recent study using a model of
neuromyelitis optica (NMO) also suggests a key role for
complement in the mechanism of antibody-mediated
inflammation in the CNS [20]. Saadoun et al. [36] dem-
onstrated that intracerebral injection of human IgG into
mouse brain only induces pathology when co-injected with
human complement. The pathology was characterized by
infiltration of monocytes, but not granulocytes, and ipsi-
versive rotation behaviour, similar to our study. FccRs
display highest affinity to IgG of the same species [1]
possibly explaining why human antibody alone did not
induce pathology, while mouse antibodies in our study
do so.
Initiation of antibody-mediated neuroinflammation
Immunohistochemical data show that immune complexes
deposit in the brain parenchyma within 24 h after antigen
challenge. We cannot rule out that the use of a micropipette
for intracerebral OVA challenge induces BBB leakage.
However, immune complexes were not observed solely in
the injection site, but observed throughout the challenged
hemisphere. In addition, intra-vitreous injections that do
not damage the blood–retinal barrier (BRB) lead to a
similar inflammatory response (unpublished observations),
suggesting an alternative mechanism for increased IgG
influx into the CNS. It is generally believed that circulating
antibodies are restricted to enter the brain due to an intact
BBB, but it has been shown that very low levels of IgG
(*0.1 %) can gain access to the brain via the extracellular
pathway [5]. We show that mice used in our study have
high serum titers of OVA-specific antibodies, and under
these conditions, the low level of IgG that crosses the intact
BBB is possibly sufficient to initiate the deposition of
immune complexes. The perivascular space is likely the
primary site of immune complex-induced inflammation as
we find constitutive and then rapidly increased expression
of FccR on perivascular macrophages. It has also been
suggested that activated T cells play a role the breaking the
integrity of the BBB in models of auto-immune-mediated
neurological diseases. Hu et al. [18] show that in the
presence of antigen, activated T cells extravasate into
ocular tissue, resulting in a monocyte recruitment and
further breakdown of the BRB. Similar findings have been
described in animal models of demyelination in the spinal
cord [44], but high numbers (3–5 9 106) of T cells were
needed to induce opening of the BBB. We detected small
numbers of CD3? T cells in our model, therefore, we
cannot exclude a role for T cells in altering BBB per-
meability and increased IgG influx. However, CD3? T
cells were also observed in FccR-/-, suggesting that
increased microglial activation depends on interaction
with FccRs.
Antibody-mediated neuropathology
In the present study we show that OVA-anti-OVA immune
complexes-induced expression of CD11b, CD68, MHC
class II as well as marked expression levels of FccRs on
microglia. Similar results have been reported following
intracerebral injection of anti-Ab antibodies in APP
transgenic mice [49]. Humoral components have been
implicated in the pathogenesis of neurodegenerative dis-
eases although it is controversial as to what extent the
antibodies are pathogenic or simply a consequence of the
ongoing neurodegeneration [11]. Engelhardt et al. [13]
showed loss of cholinergic neurons following injection of
IgG isolated from an AD patient. Similar observations were
made using IgG derived from PD patients resulting in
microglial activation and loss of hydroxylase (TH?) neu-
rons. Intracerebral administration of PD-derived IgG
Fig. 8 Behavioural changes after intracerebral injection of OVA in
OVA-immunized wild-type or Fcc-/- mice. The number of left and
right turns was measured at baseline (-1 day) and then at day 3, day
7 and day 10 after intracerebral injection of OVA in OVA-immunized
WT or Fcc-/- mice. LPS was given intraperitoneally at a dose of
100 lg/kg and rotation behaviour was tested 3 h after injection. Data
is presented as the ratio of left and right turns during a 1-min test.
Statistical analysis: One-way ANOVA, Dunnett’s post-test, n = 6 per
time point, *p\0.05. The experiment was performed twice indepen-
dently and results of experiments are pooled for the analysis
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results in perivascular inflammation, significant microglial
activation and increased rotational behaviour [9]. Interest-
ingly, the effects on microglial activation were absent in
FccR-/- mice [16]. Postmortem analysis of PD brain tissue
shows similar histopathological changes as those observed
in the animal models [22]. These observations suggest that,
apart from classic CNS autoimmune disorders, immune
complexes may contribute to the pathogenesis and/or
ongoing pathology of neurodegenerative diseases.
Implications for immunotherapy
There is growing academic and commercial interest in
utilizing the power of antibodies to treat AD by vaccination
against Ab peptides [37] but immunotherapy targeting of
brain antigens is not without risks. Histological examina-
tion of the brains of immunized humans reveals that,
although immunization reduces the plaque load in the
parenchyma [29], vascular Ab deposits persist, leading to
increased incidence of haemorrhages [6]. Experimental
models have shown that antibodies devoid of the Fc region,
such as Fab0, F(ab0)2 and scFv antibodies, or de-glycosyl-
ated antibodies, which cannot engage effector systems,
successfully remove Ab from the brain without inducing
haemorrhages [14, 33, 45]. Furthermore, increased expres-
sion of FccR expression levels are reported following
passive immunization with Ab-specific antibodies in APP
transgenic mice, which did not occur after deglycosylation
of the therapeutic antibody [8, 48]. These observations
suggest that antibodies facilitate in the removal of plaques,
but their Fc regions can cause detrimental inflammatory
reactions through interaction with perivascular macro-
phages and microglia. Another potential side-effect of
immunotherapy is the solubilization of Ab peptides from
plaques that remain trapped in the perivascular drainage
pathways, leading to worsening of cerebral amyloid angi-
opathy [6]. We hypothesize that formation of immune
complexes between Ab peptides and Ab antibodies and
subsequent inflammation may partly explain increased
CAA following immunotherapy. A better understanding
of FccRs and controlling FccR function in the brain
microenvironment will likely increase the success of
immunotherapy for neurodegenerative diseases and reduce
clinical setbacks experienced to date.
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